News Nurix Therapeutics, Inc.

Equities

NRIX

US67080M1036

Real-time Estimate Cboe BZX Other stock markets 09:25:20 29/04/2024 pm IST			5-day change	1st Jan Change
12.7 ^USD	+2.79%		-6.85%	+22.58%

12/04	Sector Update: Health Care Stocks Steady Pre-Bell Friday	MT
12/04	Sector Update: Health Care	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	17/04	AQ
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering	15/04	AQ
Sector Update: Health Care Stocks Steady Pre-Bell Friday	12/04	MT
Sector Update: Health Care	12/04	MT
North American Morning Briefing : Big Banks Kick off Earnings Season	12/04	DJ
Nurix Therapeutics Prices Upsized Stock Offering at $15 a Share	12/04	MT
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering	12/04	AQ
Nurix Therapeutics Launching Public Offering -- Shares Fall After-Hours	12/04	MT
Nurix Therapeutics Announces Proposed Public Offering	12/04	AQ
Baird Adjusts Price Target on Nurix Therapeutics to $25 From $24, Maintains Outperform Rating	11/04	MT
RBC Lifts Price Target on Nurix Therapeutics to $23 From $22, Keeps Outperform Rating, Speculative Risk Qualifier	11/04	MT
Nurix Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024	10/04	CI
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update	10/04	AQ
Earnings Flash (NRIX) NURIX THERAPEUTICS Reports Q1 Revenue $16.6M	10/04	MT
North American Morning Briefing : Traders Await -2-	10/04	DJ
Nurix Therapeutics Shares Climb 19% on Extended Sanofi Collaboration	09/04	DJ
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies	09/04	AQ
Nurix Therapeutics, Inc. Reports First Clinical Evidence of CNS Activity of NX-5948, A Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies	09/04	CI
Nurix Therapeutics Extends Collaboration With Sanofi, Aims to Nominate Clinical Candidate	09/04	MT
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6	09/04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Nurix Therapeutics, Inc.

Equities

NRIX

US67080M1036

Summary

Filters